The active substance in Dicot's drug candidate is a semi-synthetic molecule whose starting material is from nature. To manufacture the medicinal substance, the starting point is seeds that undergo an extraction process followed by a number of synthesis steps.

The seeds come primarily from South Africa where Dicot has been working for several years with established partners who handle harvesting and storage. The subsequent extraction step has so far been performed by contract manufacturer in Stockholm.

Dicot has now, after evaluation and testing, decided to move the extraction process from Sweden to a manufacturer in South Africa, which means that all the first steps in the manufacturing process take place in the same country. This change results in fewer transports, shorter lead times and lower manufacturing costs.

"Moving the extraction process to South Africa is a smart and logical decision from both a cost and environmental point of view. We have just been to South Africa and met our partners and made a site visit to the new manufacturer," comments Elin Trampe, CEO of Dicot.

For further information, please contact:

Elin Trampe, CEO
Tel: +46 739 80 14 08
Email: elin.trampe@dicot.se

About Dicot AB

Dicot is developing the drug candidate LIB-01, which will be a potency agent to better treat erectile dysfunction and premature ejaculation. The ambition is to create a drug with significantly longer effect and far fewer side effects, compared to those on the market. Today, at least 500 million men suffer from these sexual dysfunctions and the market is valued at SEK 50 billion. Research and development are conducted under own auspices up to phase 2 studies. Thereafter, Dicot's intention is to form strategic alliances, or alternatively carry out a trade sale, with larger, established pharmaceutical companies to be able to introduce LIB-01 on the world market.

Dicot is listed on Spotlight Stock Market and has approximately 3,300 shareholders. For more information, please visit www.dicot.se.